New MASH drug development could reshape the treatment paradigm
The development of therapies for metabolic dysfunction-associated steatohepatitis (MASH) has entered an exciting new phase with several critical Phase III trials now underway. These trials are poised to revolutionise the approach to MASH, a disease …